Aqua's acquisition to push Almirall in US dermatology market

3 April 2014

Spain’s largest drugmaker, Almirall (ALM: MC), announced at the end of last year the acquisition of Aqua Pharmaceuticals, a privately-held company based in the USA and focused mainly on acquiring, developing and marketing branded prescription dermatology products (The Pharma Letter December 17, 2013). TPL’s Spain correspondent now takes a deeper look into the company.

Under the terms of the agreement, Barcelona-based company paid an upfront cash consideration of $305 million, and also there will be an additional upfront payment of $22.6 million related to amortization of certain long term tax assets. Additional potential payments up to $75 million may be due if some regulatory and commercial milestones are met during the period 2014-2015.

Aqua’s profile

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK